Solcoseryl Jelly/Solcoseryl Ointment

Solcoseryl Jelly/Solcoseryl Ointment

Manufacturer:

A. Menarini

Distributor:

Zuellig Pharma

Marketer:

A. Menarini
Full Prescribing Info
Contents
Protein-free haemodialysate.
Description
1 g of Solcoseryl Jelly contains: 4.15 mg of protein-free haemodialysate from calves' blood, chemically and biologically standardized; 1.73 mg of methyl parahydroxybenzoate (E 218); 0.27 mg of propyl parahydroxybenzoate (E 216).
1 g of Solcoseryl Ointment contains: 2.07 mg of protein-free haemodialysate from calves' blood, chemically and biologically standardized; 1.6 mg of methyl parahydroxybenzoate (E 218); 0.2 mg of propyl parahydroxybenzoate (E 216).
Action
Pharmacology: Pharmacodynamics: Solcoseryl is a protein-free haemodialysate and contains a large number of low-molecular components of cells and serum of calf blood (dialysis/ultrafiltration, cut-off 5,000 Da), which until now have only partly been characterized chemically and pharmacologically.
In various cell and tissue cultures, in organs and in the animal organism, it was found that Solcoseryl: fosters/stimulates the aerobic energy metabolism and oxidative phosphorylation and thus the provision of high-energy phosphates in undersupplied cells,
Increases oxygen utilization (in vitro) and glucose transport in hypoxic and metabolically depleted tissues and cells,
Improves the processes of repair and regeneration of damaged and/or under-served tissue,
Prevents or reduces secondary degeneration and pathological changes in reversibly damaged cell systems,
Increases collagen synthesis in in vitro models, and
Stimulates cell proliferation and migration in vitro.
Solcoseryl thus promotes the re-functionalization of hypoxia and/or lack of substrate of reversibly damaged tissue and speeds up as well as improves the quality of the healing of lesions.
Pharmacokinetics: Absorption, distribution and elimination of the protein-free haemodialysate active ingredient cannot be analysed by conventional pharmacokinetic methods such as radioactive labeling etc. because protein-free haemodialysate has a variety of pharmacodynamic effects which are attributable to molecules with different physiochemical properties.
Indications/Uses
Solcoseryl Jelly and Ointment contain a haemodialysate from calves' blood to promote healing.
The products are suitable for treating minor and poorly healing wounds and ulcers of the skin.
Solcoseryl Jelly
promotes wound healing. The Jelly is particularly used for treating venous stasis ulcers, decubital ulcers, acute and chronic dermatitis, secondary and tertiary burns.
Solcoseryl Ointment promotes the healing of dry wounds. It is particularly suitable for minor burns and abrasions. It is used in combination with the Jelly for deep, poorly healing wounds to protect the newly formed skin. This reduces the healing time and results in cosmetic improvement in the scarring.
Dosage/Direction for Use
Recommended Dosage: Solcoseryl Jelly is applied thinly 2-3 times a day.
Duration of treatment: until fresh skin tissue has formed. It is advisable to cover the newly formed skin at the edge of the poorly healing wounds and ulcers using Solcoseryl Ointment. Before application of the product, recent, weeping abrasions should be dried with a clean piece of gauze.
Solcoseryl Ointment
is applied thinly 1-2 times a day and covered with a dressing. Do not massage in.
Duration of treatment:
until the wound has completely healed.
Use the dosage indicated in this package insert or prescribed by the physician. If the patient thinks the effect of the medicine is too weak or too strong, speak to the physician or pharmacist.
Route of administration: Topical use.
Overdosage
Toxic effects from overdosage of Solcoseryl Jelly or Ointment have not been reported.
Contraindications
In cases of hypersensitivity or allergy to parahydroxybenzoates (E 210, E 216, E 218) which are present as preservatives.
Special Precautions
No special precautions are necessary on use in accordance with the instructions.
Use In Pregnancy & Lactation
Reproduction studies in animals have not shown any risks to the fetus, but there are no controlled studies in pregnant women. When used in pregnancy caution must exercised. There are no concerns with the application of Solcoseryl Jelly and Ointment during lactation.
Adverse Reactions
In very rare cases, hypersensitivity reactions may occur. If unusual skin reactions occur, discontinue the product and inform the physician or pharmacist. After application of Solcoseryl Jelly, an unpleasant stinging may occur for a short time. This does not mean the product should be discontinued.
Drug Interactions
No interactions with other agents have been reported.
Storage
The medicine should be stored at temperature below 30°C.
Shelf-Life: 5 years.
ATC Classification
D03AX - Other cicatrizants ; Used in the treatment of wounds and ulcers.
Presentation/Packing
Solcoseryl Jelly 4.15 mg (colourless, homogenous, clear gel of high consistency) x 20 g. Solcoseryl Ointment 2.07 mg (white to slightly yellowish, homogenous, fatty mass and is easily spreadable) x 20 g.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in